Chinese patent granted for anti-LAG-3 antibody LAG525
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- INSIGHT-003 investigator-initiated trial - 1st patient dosed
- Completion of Placement - Tranche 2
- Completion of Share Purchase Plan
- US FDA & IRB approves start of ph2b head & neck cancer trial
- Efti to be evaluated in new triple combination therapy trial
Later from Immutep
- Immuteps partner, EOC Pharma, expands efti trial pipeline
- Recruitment of patients completed for Part B of TACTI-002
- Immutep Receives A$3.4 million R&D French Tax Incentive
- Immutep Quarterly Activities Report & Appendix 4C
- Immutep receives EMA scientific advice for Phase 3 in MBC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep